TrialsgrambetaRCTs are beautiful

REMAP-CAP (IL-6)

2021

Tocilizumab or Sarilumab in Critically Ill COVID-19

In 803 critically ill ICU COVID-19 patients within 24 h of organ support, tocilizumab or sarilumab improved organ-support-free days and hospital survival versus control.

Result

Primary endpoint: Organ-support-free days at 21 days

Median organ-support-free days 10 (tocilizumab) and 11 (sarilumab) vs 0 (control); adjusted cumulative OR 1.64 (95% CrI 1.25-2.14) and 1.76 (95% CrI 1.17-2.91). Pooled 90-day survival HR 1.61 (95% CrI 1.25-2.08).

Original publication
Subtopic
IL-6 antagonists
Design
Adaptive platform RCT (REMAP-CAP)
Relevance
Important: one of several pillars.
Source
REMAP-CAP Investigators. N Engl J Med. 2021;384(16):1491-1502.doi 10.1056/NEJMoa2100433

Discussion & critique

Together with RECOVERY-Toci, the basis for routine IL-6 blockade in deteriorating COVID-19.

Discussed in podcasts